Education
About Us
Working with TipRanks
Follow Us
Biocryst Pharmaceuticals (BCRX)
NASDAQ:BCRX
BCRX Stock Chart & Stats
$7.10
-$0.02(-0.25%)
At close: 4:00 PM EST
$7.10
-$0.02(-0.25%)
Day’s Range― - ―
52-Week Range$6.00 - $11.31
Previous CloseN/A
Volume537.69K
Average Volume (3M)5.49M
Market Cap
$1.49B
Enterprise Value$2.14B
Total Cash (Recent Filing)$212.87M
Total Debt (Recent Filing)$683.11M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Feb 25, 2026EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding210,543,230
10 Day Avg. Volume3,858,382
30 Day Avg. Volume5,487,957
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-3.27
Price to Sales (P/S)3.45
P/FCF Ratio-29.25
Enterprise Value/Market Cap1.43
Enterprise Value/Revenue3.57
Enterprise Value/Gross Profit3.66
Enterprise Value/Ebitda25.50
Forecast
1Y Price Target
$19.27Price Target Upside171.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)0.12
Revenue Forecast (FY)$619.70M
Bulls Say, Bears Say
Bulls Say
Acquisition StrategyBioCryst Pharmaceuticals is acquiring ATXS to bring in navenibart, a plasma kallikrein mAb with strong potential in HAE prophylaxis.
Market PositioningOrladeyo and navenibart each represent potential $1 billion peak drugs, solidifying BioCryst's position in the HAE market.
Product Pipeline ExpansionNavenibart has shown compelling proof of concept, with a high conviction for competitive efficacy in the Phase III ALPHA ORBIT study.
Bears Say
Competitive ConcernsThe current stock reaction reflects competitive fears regarding Orladeyo and navenibart, along with controversy on peak sales expectations.
Market ReactionToday's stock reaction reflects competitive fears on both Orladeyo/navenibart and corresponding controversy on peak sales.
Sales OutlookA slight Q/Q tickdown in Orladeyo sales is expected in 4Q25 to reflect the sale divestment of its EU business.
BioCryst News
BCRX FAQ
What was Biocryst Pharmaceuticals’s price range in the past 12 months?
Biocryst Pharmaceuticals lowest stock price was $6.00 and its highest was $11.31 in the past 12 months.
What is Biocryst Pharmaceuticals’s market cap?
Biocryst Pharmaceuticals’s market cap is $1.49B.
When is Biocryst Pharmaceuticals’s upcoming earnings report date?
Biocryst Pharmaceuticals’s upcoming earnings report date is Feb 25, 2026 which is in 89 days.
How were Biocryst Pharmaceuticals’s earnings last quarter?
Biocryst Pharmaceuticals released its earnings results on Nov 03, 2025. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.04 by $0.02.
Is Biocryst Pharmaceuticals overvalued?
According to Wall Street analysts Biocryst Pharmaceuticals’s price is currently Undervalued.
Does Biocryst Pharmaceuticals pay dividends?
Biocryst Pharmaceuticals does not currently pay dividends.
What is Biocryst Pharmaceuticals’s EPS estimate?
Biocryst Pharmaceuticals’s EPS estimate is 0.03.
How many shares outstanding does Biocryst Pharmaceuticals have?
Biocryst Pharmaceuticals has 210,543,230 shares outstanding.
What happened to Biocryst Pharmaceuticals’s price movement after its last earnings report?
Biocryst Pharmaceuticals reported an EPS of $0.06 in its last earnings report, beating expectations of $0.04. Following the earnings report the stock price went down -6.284%.
Which hedge fund is a major shareholder of Biocryst Pharmaceuticals?
Currently, no hedge funds are holding shares in BCRX
BioCryst Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.27 (171.41% Upside)
$19.27 (171.41% Upside)
Blogger Sentiment
Bullish
BCRX Sentiment 60%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 7.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.4%
Last 30 Days ▲ 11.2%
Last 30 Days ▲ 11.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.13%
Trailing 12-Months
Company Description
Biocryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for rare diseases, particularly those related to genetic disorders and viral infections. The company's core products include Orladeyo (berotralstat), an oral medication approved for the prevention of hereditary angioedema attacks, and other pipeline candidates aimed at treating conditions such as COVID-19 and various forms of cancer. BioCryst operates primarily in the pharmaceutical sector, leveraging its proprietary drug development technologies to address unmet medical needs.
BCRX Company Deck
BCRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a strong performance by BioCryst with significant revenue growth, successful financial maneuvers, and promising pipeline developments. However, there were some challenges, including enrollment delays and increased costs. Overall, the company's positive results and strategic decisions indicate a promising outlook.View all BCRX earnings summariesBCRX Stock 12 Month Forecast
Average Price Target
$19.27
▲(171.41% Upside)
Technical Analysis
Vericel
―
Celldex
―
Sarepta Therapeutics
―
Aurinia Pharmaceuticals
―
Cidara Therapeutics
―
Ownership Overview
1.76% Insiders
17.17% Mutual Funds
27.78% Other Institutional Investors
35.75% Public Companies and Individual Investors